ALK and non-small cell lung carcinoma: Having summarised the lorlatinib data from AACR 2018, Dr Martini went on to summarise the findings from the JAVELIN trial presented by Dr Shaw at ASCO 2018 [5], which showed the combination of avelumab and lorlatinib for heavily pre-treated ALK + NSCLC patients was safe, with an ORR for 46%, but has not improve overall response of clinical response rates with data still maturing.